UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 10, 1996 (May 8, 1996)
ARTERIAL VASCULAR ENGINEERING, INC.
(Exact name of registrant as specified in its charter)
0-27802
(Commission File Number)
Delaware 94-3144218
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
5355 Skylane Boulevard, Santa Rosa, California 95403
(Address of principal executive offices) (Zip code)
(707) 525-0111
(Registrant's telephone number, including area code)
<PAGE>
Item 4. Changes in Registrant's Certifying Accountants
(a) Effective May 9, 1996, the Board of Directors of Arterial
Vascular Engineering, Inc. engaged the accounting firm of
Ernst & Young L.L.P. as independent public accountants for
the Registrant. Coopers & Lybrand L.L.P. were terminated
effective May 8, 1996. The Registrant's audit committee
approved these actions.
(b) During the two most recent fiscal years and subsequent
interim periods prior to May 8, 1996 there were no
disagreements with Coopers & Lybrand L.L.P. on any matter
of accounting principles or practices, financial statement
disclosure, auditing scope or procedure, or any reportable
events.
(c) The report of Coopers & Lybrand L.L.P. on the financial
statements of the Registrant for the past two years
contained no adverse opinion or other disclaimer of
opinion and was not qualified or modified as to
uncertainty, audit scope or accounting principles.
(d) The Registrant has not consulted with Ernst & Young L.L.P.
during the last two years or subsequent interim period on
either the application of accounting principles or type of
opinion Ernst & Young L.L.P. might issue on the
Registrant's financial statements.
(e) The Registrant requested that Coopers & Lybrand L.L.P.
furnish a letter addressed to the SEC stating whether they
agree with the above statements. A copy of the Coopers &
Lybrand L.L.P. letter to the SEC, dated May 10, 1996, is
filed as an exhibit to this Form 8-K.
Item 7. Financial Statements and Exhibits
Exhibit
16.2 Letter re change in Registrant's certifying accountants.
Page 2
<PAGE>
INDEX TO FINANCIAL STATEMENTS AND EXHIBITS
Exhibit Sequential
Number Description Page Number
- - ------- ----------- -----------
16.2 Letter re change in certifying accountants 5
Page 3
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ARTERIAL VASCULAR ENGINEERING, INC.
Date: May 10, 1996 /S/ John D. Miller
------------------
John D. Miller
Vice President Finance, Chief Financial Officer
Page 4
<TABLE>
<CAPTION>
<S> <C> <C> <C>
Coopers Coopers & Lybrand L.L.P. Ten Almaden Boulevard telephone (408) 295-1020
& Lybrand a professional services firm Suite 1600 facsimile (408) 292-1382
San Jose, Ca 95113
3000 Sand Hill Road
Building 2, Suite 150 telephone (415) 493-1552
Menlo Park, Ca 94025 facsimile (415) 854-3623
</TABLE>
May 10, 1996
Securities and Exchange Commission
450 5th Street, N.W.
Washington, D.C. 20549
Gentlemen:
We have read the statements made by Arterial Vascular Engineering, Inc. (copy
attached), which we understand will be filed with the Commission, pursuant to
Item 4 of Form 8-K, as part of the Company's Form 8-K report for the month of
May 1996. We agree with the statements concerning our Firm in such Form 8-K.
Very truly yours,
/s/ Coopers & Lybrand L.L.P
Coopers & Lybrand L.L.P. is a member of Coopers & Lybrand International, a
limited liability association incorporated in Switzerland.
Page 5
